Gene Hung

This inventor holds 34 USPTO granted patents and 12 published patent applications and 10 EPO patents, primarily in Gene Therapy. Top assignees: Ionis Pharmaceuticals, Inc., Alumis Inc., Isis Pharmaceuticals, Inc.. Active years: 2014-2026.

USPTO Granted Patents = 34 (Patent Applications = 12)

% Patents Active = 88.2

EPO Patents = 10 (Patent Applications = 16)

Average Co-Inventor Count = 4.0

ph-index = 8

Forward Citations = 184(Granted Patents)

Location History:

Carlsbad, CA (US) (2014 - 2022)
San Diego, CA (US) (2014 - 2024)
San Francisco, CA (US) (2023 - 2024)

Company Filing History:

15 out of 287

Ionis Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

Chdi Foundation, Inc.

patents

6. 2 out of 196

Cold Spring Harbor Laboratory

patents

7. 2 out of 2

Fronthera U.S. Pharmaceuticals LLC

patents

8. 2 out of 8

Sichuan Haisco Pharmaceutical Co., Ltd.

patents

9. 2 out of 1,685

University of Utah Research Foundation

patents

10. 2 out of 2

Xizang Haisco Pharmaceutical Co., Ltd.

patents

11. 1 out of 1

Esker Therapeutics, Inc.

patent

12. 1 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Huntingtin Modulation

TYK2 Inhibitors

PMP22 Expression

Ataxin 2

SMN2 Splicing

Prion Expression

Thyroid Hormone Agonists

Autotaxin Inhibitors

Apoptosis Regulation

Hemoglobin Modifiers

Substituted Triazoles

Substituted Pyridines

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679850 - TYK2 inhibitors and uses thereof (2026-07-14),

2. 12529055 - METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION (2026-01-20),

3. 12509681 - Antisense oligonucleotides directed to huntingtin (2025-12-30),

4. 12358899 - Thyroid hormone receptor agonists and uses thereof (2025-07-15),

5. 12351572 - Substituted 1,2,4-triazoles as TYK2 inhibitors (2025-07-08),

6. 12297431 - Modulation of huntingtin expression (2025-05-13),

7. 12060343 - Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors (2024-08-13),

8. 12006306 - Substituted pyridazines as TYK2 inhibitors (2024-06-11),

9. 11964964 - Thyroid hormone receptor agonists and uses thereof (2024-04-23),

10. 11959080 - Methods and compositions for inhibiting PMP22 expression (2024-04-16),

11. 11834660 - Compositions for modulating Ataxin 2 expression (2023-12-05),

12. 11731956 - Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors (2023-08-22),

13. 11421231 - Modulation of Huntington expression (2022-08-23),

14. 11136577 - Methods and compositions for inhibiting PMP22 expression (2021-10-05),

15. 11053219 - Substituted pyridines as TYK2 inhibitors (2021-07-06),

Title: Gene Hung: Innovator in Thyroid Hormone Research

Introduction

Gene Hung, an accomplished inventor based in San Diego, California, has made significant contributions to the field of medical research with a focus on thyroid hormone-related therapies. With an impressive portfolio of 25 patents, Gene continues to advance our understanding of thyroid hormone receptor activity and its implications for treating various medical conditions.

Latest Patents

Among Gene's latest patents are groundbreaking innovations in the treatment of diseases associated with thyroid hormone receptor activity. One notable patent details methods and compositions for utilizing thyroid hormone receptor agonists to treat conditions, diseases, or disorders linked to thyroid hormone receptor functionality. Additionally, he has developed methods and compounds for inhibiting PMP22 expression, providing potential treatments for diseases associated with this specific protein.

Career Highlights

Gene Hung has had a prominent career in the pharmaceutical industry, working with renowned organizations such as Ionis Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. His research and innovations have earned him respect and recognition within the field of medical sciences, particularly in areas focused on endocrine health.

Collaborations

Throughout his career, Gene has collaborated with notable professionals including C Frank Bennett and Susan M Freier. These partnerships have facilitated the successful development of innovative treatments and have contributed to the advancement of research in hormone receptor therapies.

Conclusion

Gene Hung stands out as a pivotal figure in the field of medical research, particularly with his focus on thyroid hormone receptor activity. With a strong patent portfolio that reflects his commitment to innovation, he continues to make strides in developing therapies that address crucial health issues. His work exemplifies the importance of collaboration and innovation in the advancement of medical science.